Smart Nanoparticles Reprogram Tumour Defenses to Boost Immune Attack on Cancer

Scientists at Adelaide University have unveiled a new mRNA-based strategy that could reshape one of the most stubborn obstacles in cancer treatment: the hostile environment that tumours build around themselves to keep the immune system at bay. In a study published in Science Advances, a multidisciplinary team spanning chemical engineering, biomedical science, oncology and immunology describes tiny lipid nanoparticles engineered to seek out tumour-associated macrophages, immune cells that tumours co-opt as allies, and reprogram them from within so they actively summon cancer-killing T cells into the tumour. The work, led by Professor Chunxia Zhao of the university’s School of Chemical Engineering, offers a compelling proof of concept that the same delivery technology behind mRNA vaccines can be redirected to rewrite the immunological rules of a tumour rather than simply attacking its cells directly.

The challenge the researchers set out to address is well known to immunotherapy researchers. Checkpoint-blocking drugs have transformed outcomes for some patients with melanoma, lung cancer and other malignancies, but many solid tumours remain resistant because their surroundings actively suppress immune activity. Tumour-associated macrophages, or TAMs, are abundant white blood cells found inside tumours that, in their tumour-associated state, help the cancer evade destruction. Professor Zhao explained the central problem succinctly: the immune system may be fully capable of attacking a tumour, but the tumour environment can stop those immune cells from doing their job. Her team’s answer was to change that environment from within, delivering treatment precisely to the cells that maintain the immunosuppressive order and persuading them to switch sides.

The delivery vehicle at the heart of the study is the lipid nanoparticle, the same class of fatty droplet that carries mRNA in COVID-19 vaccines. But these particles were given a targeting upgrade: their surface is coated with an antibody that recognises TREM2, a protein expressed at high levels on tumour-associated macrophages. This molecular address label guides the nanoparticles to the very cells responsible for tumour immune suppression. Once inside the macrophages, the particles release two payloads with complementary functions. The first is an mRNA molecule carrying instructions for the macrophage to produce CXCL9, a chemical signalling protein. The second is Resiquimod, a small-molecule compound that pushes macrophages away from their immune-suppressing behaviour and toward a more inflammatory, immune-supportive state.

The two payloads work in concert in a way that illustrates the elegance of the design. CXCL9 acts as a chemical beacon, drawing cytotoxic CD8+ T cells, the immune system’s primary tumour-killing soldiers, into the tumour mass, where they are often excluded or rendered inactive. Meanwhile, Resiquimod shifts the local macrophage population away from suppression, easing the hostile conditions that would normally exhaust or repel those T cells. Rather than depleting the macrophages outright, an approach that can carry inflammatory side effects, the researchers effectively re-educated them, converting a tumour-protective population into an accomplice of the anti-cancer immune response.

In experiments with mouse models, the approach produced measurable shifts in the tumour immune landscape. Treatment reduced the proportion of immune-suppressing macrophages by more than 60 percent, a substantial remodelling of the tumour’s defensive cellular makeup. Levels of CXCL9 within the tumours rose fourfold, confirming that the delivered mRNA was being translated into functional chemical beacon by the targeted cells. The researchers also documented greater numbers and heightened activity of cancer-fighting T cells inside the treated tumours, along with a moderate reduction in tumour growth. While the growth slowdown alone was not dramatic, the immunological changes suggest a tumour environment becoming markedly more permeable and hospitable to immune attack.

The team then tested whether their nanoparticle therapy could amplify the effects of existing immunotherapies. When combined with immune checkpoint-blocking antibodies targeting PD-L1 and CTLA-4, two of the most widely used targets in clinical oncology, the treatment produced further increases in cytotoxic T cells and, notably, the generation of central memory T cells. These long-lived memory cells could give the immune system the ability to recognise and respond to cancer if it returns, a property highly valued in cancer therapy because it hints at durable protection rather than transient tumour shrinkage. Interestingly, however, the combination did not yield additional tumour-growth inhibition in this particular mouse model, a nuance the researchers report candidly and one that will guide future experimental design.

Professor Zhao framed the findings as an important proof of concept that mRNA and nanoparticle technology can reprogramme the immune environment of a tumour. She emphasised that significant work remains before the approach could be considered for patients, but described the results as an encouraging foundation for developing more targeted cancer immunotherapies. That caution reflects the well-known gap between promising mouse studies and clinical reality: nanoparticle manufacturing, dosing, safety profiling and the variability of human tumour environments all present substantial hurdles. Still, the strategy addresses a specific failure mode of current immunotherapy, immune exclusion, and does so with a precision that conventional drugs have struggled to achieve.

The broader significance of the work lies in the expanding repertoire of mRNA medicine. The pandemic demonstrated that lipid nanoparticles can deliver genetic instructions safely and at scale; researchers worldwide are now exploring whether the same platform can carry therapeutic instructions for enzymes, antibodies, cytokines and tumour antigens. This study adds a subtle new use case: not delivering a drug or an antigen, but delivering the blueprint for a signalling molecule that changes the behaviour of the cells receiving it. By targeting TREM2-positive macrophages, the Adelaide team also taps into a growing body of research on macrophage reprogramming, an area increasingly seen as fertile ground for solid tumour therapy where T-cell-focused approaches alone often fall short.

The research was led by Adelaide University scientists in collaboration with SA Pathology and the Royal Adelaide Hospital, and is published under the title ‘Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy’. For patients whose tumours shut out immunotherapy, the study offers a vision of treatment that does not fight the tumour’s fortress head-on but instead quietly converts its guards, arming them with the instructions to raise a signal flare that guides the immune system’s most lethal cells inside. If subsequent studies can translate those beacon-lit results into durable clinical benefit, mRNA nanoparticles may find a second act in oncology as architects of the tumour microenvironment rather than mere couriers of vaccines.

The biology underlying the study helps explain why macrophages have become such a sought-after target. Macrophages are not inherently tumour-friendly; in healthy tissue they patrol, clear debris and coordinate inflammatory responses. Tumours, however, gradually reshape the macrophages they recruit, coaxing them into a state that suppresses cytotoxic T cells, promotes new blood vessel growth and remodels the fibrous matrix surrounding the cancer. High densities of these suppressive macrophages have been associated in many cancer types with poorer responses to checkpoint inhibitors, which is why strategies that convert rather than eliminate them have attracted growing interest.

The choice of TREM2 as a targeting marker reflects recent advances in understanding macrophage identity within tumours. TREM2 is a receptor expressed on a subset of macrophages that accumulates in tumours and is linked to immunosuppressive function, and blocking or depleting TREM2-positive cells has emerged as an active area of preclinical investigation. Using an antibody against TREM2 as a homing device, rather than as a therapeutic agent itself, is a distinctive feature of the Adelaide approach: the antibody serves as an address label that concentrates the therapeutic payload where it is most needed, potentially limiting off-target effects in healthy tissue.

The signalling components of the formulation also draw on established immunology. Resiquimod is a synthetic agonist of toll-like receptors, pathways that act as alarm bells for the innate immune system and have previously been explored as topical treatments and vaccine adjuvants. Encapsulating it alongside mRNA allows the two stimuli to act within the same cell, pairing a behavioural switch with a genetic instruction. CXCL9, meanwhile, belongs to a family of chemokines long known for their role in recruiting CD8+ T cells to sites of inflammation, and low CXCL9 expression has been linked to immune-excluded tumours in human studies, making it a rational choice for restoring T-cell infiltration.

The appearance of central memory T cells in the combination experiments deserves particular attention. Memory T cells persist long after an initial immune response subsides and can mount faster, stronger reactions upon re-encounter with their target. In cancer, inducing such cells is a goal of therapeutic approaches such as cancer vaccines and intratumoural therapies, because tumour recurrence remains a leading cause of treatment failure even when initial therapy is successful. The fact that this memory phenotype emerged despite the absence of added tumour shrinkage suggests that immunological benefit and immediate tumour control may follow different timelines, a distinction that longer animal studies would need to resolve.

The candid reporting of the combination result also illustrates a broader principle in immunotherapy research: immune activation and tumour regression are not always tightly coupled in early experiments. Factors such as the mouse model used, the timing of treatment relative to tumour establishment, and the dose and schedule of each component can all influence whether enhanced T-cell activity translates into measurable growth control. The authors’ decision to publish these nuances alongside the positive findings provides a transparent baseline for other laboratories seeking to refine the formulation, test it across additional tumour types, and determine which patient populations might ultimately benefit most from a macrophage-reprogramming strategy.

Subject of Research: mRNA lipid nanoparticle reprogramming of tumour-associated macrophages for cancer immunotherapy.

Article Title: New ‘smart’ nanoparticles help the immune system better attack tumours

Article References: New ‘smart’ nanoparticles help the immune system better attack tumours. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lipid nanoparticles, mRNA, tumour-associated macrophages, cancer immunotherapy, CXCL9, TREM2, CD8+ T cells, immune checkpoint inhibitors, tumour microenvironment, Resiquimod, Science Advances, Adelaide University